Hybrid Immunity Provides the Best COVID-19 Humoral Response in Immunocompromised Patients with or without SARS-CoV-2 Infection History

Immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly limited the spread of coronavirus disease 2019 (COVID-19) and reduced the associated complications, especially mortality. To prolong immunity, an immune booster was implemented. We evaluated the role...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2023-08, Vol.11 (8), p.1380
Main Authors: Nazaruk, Paulina, Tkaczyk, Ignacy, Monticolo, Marta, Jędrzejczak, Anna Maria, Krata, Natalia, Pączek, Leszek, Foroncewicz, Bartosz, Mucha, Krzysztof
Format: Article
Language:English
Subjects:
Analysis
Antibodies
BNT162b2 mRNA vaccine
Body mass index
chronic kidney disease
Coronaviruses
COVID-19
COVID-19 vaccines
Creatinine
Demographic aspects
Health aspects
Immune response
Immune response (humoral)
Immunity
Immunization
Immunocompromised host
Immunocompromised hosts
Immunoglobulin A
Infections
Kidney diseases
Kidney transplantation
Kidneys
Laboratories
Liver transplantation
Nephropathy
Normal distribution
Respiratory diseases
SARS-CoV-2
Schedules
Severe acute respiratory syndrome coronavirus 2
Transplantation
Vaccines
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly limited the spread of coronavirus disease 2019 (COVID-19) and reduced the associated complications, especially mortality. To prolong immunity, an immune booster was implemented. We evaluated the role of SARS-CoV-2 infection history in the vaccination schedules of kidney and liver transplant recipients and patients with chronic kidney disease (CKD). To this end, we retrospectively analyzed the data of 78 solid organ transplantation (SOT) recipients and 40 patients with immunoglobulin A (IgA) nephropathy as representatives of the CKD group. Patients received two or three doses of the BNT162b2 vaccine. At the follow-up, antibody (Ab) titer, graft function, COVID-19 history, and patients’ clinical condition were assessed. Ab level was higher after two doses in patients with a COVID-19 history over three doses in patients with no COVID-19 history. Compared to three doses, subjects who were administered two doses had a longer median time to infection. Positive antibodies, in response to the third dose, were not observed in up to 8.4% of SOT patients. The results show that the vaccination schedule should take into account the vaccine response rate and COVID-19 history. So-called hybrid immunity appears to be most efficient at providing humoral responses against SARS-CoV-2 infection in immunocompromised patients.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11081380